Ellie Leick


Navigating COVID-19 Challenges to Provide Optimal Cancer Care

April 26th 2020

Gilberto De Lima Lopes, MD, discusses the impact of COVID-19 on his practice and how he is coping with the changes caused by the pandemic.

Transplant Considerations in Hematologic Malignancies in Light of COVID-19

April 20th 2020

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

April 18th 2020

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Novel Therapies Expand Options in Melanoma, But Surgery Retains Role

April 16th 2020

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Stem Cell Mobilization Strategies Call for Careful Consideration in Myeloma

April 15th 2020

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Managing Treatment Toxicity in CML and MPNs

April 14th 2020

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

COVID-19 Causes Shifts in Clinical Trial Practices

April 13th 2020

Shilpa Gupta, MD, discusses the modifications made to patient care in light of the COVID-19 pandemic, the hurdles faced with clinical trials during this time, and some of the ways in which her institution is facing the virus-related challenges head-on.

COVID-19 Challenges Change Oncology Practice

April 10th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.

ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm

April 10th 2020

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Cabozantinib Combinations Generate Excitement in RCC

April 8th 2020

Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.